SESSION III: ACUTE MYELOID LEUKEMIA

Session Chairs: Farhad Ravandi, MD and Andrew Wei, MBBS, PhD

Menin Inhibitors in NPM1 Mutated and KMT2Ar AML: Combinations and Resistance Mechanisms | Ghayas C. Issa, MD | MD Anderson Cancer Center, Houston, Texas, USA

How to Best Incorporate FLT3 Inhibitors in the Management of FLT3 Mutated AML | Alexander E. Perl, MD | University of Pennsylvania, Philadelphia, Pennsylvania, USA

IDH Inhibitor Combination Strategies in IDH Mutated AML | Courtney D. DiNardo, MD, MSCE | MD Anderson Cancer Center, Houston, Texas, USA

DEBATE: The Best Strategy Using Lower Intensity Regimens is Concomitant Therapy | Naval Daver, MD | MD Anderson Cancer Center, Houston, Texas, USA

DEBATE: The Best Strategy Using Lower Intensity Regimens is Sequential Use of Agents | Alice S. Mims, MD | Ohio State University, Columbus, Ohio, USA

Use of MRD to Guide Therapeutic Decision Making | Andrew Wei, MBBS, PhD | Peter MacCallum Cancer Centre, Melbourne, Australia

Novel Strategies in High-Risk AML- Focus on Immune-Based Strategies | David A. Sallman, MD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Improving Risk Stratification in AML and Potential Role for AI? | TBD | Institution, City, State, Country

Oral Abstract TBA | Speaker | Affiliation, City, State, Country